Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas
Phase 1
42
about 5.9 years
≤21
1 site in TN
What this study is about
This trial is testing a new treatment called B7-H3-CAR T cells, combined with radiation therapy and chemotherapy, to see if it's safe for children with certain types of cancer. The goal is to determine the safety of this combination approach in young people whose cancers have returned after other treatments.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Radiation Therapy
- 2.Take B7-H3-CAR T Cells
- 3.Take Cyclophosphamide
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cell therapy (Engineered T-cells that target specific cancer antigens), cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine
infusion
Primary: Dose limiting toxicity (DLT) rate, Incidence of adverse events (AEs)
radiation
Oncology